All News

30 September 2024

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCCAntibodies

30 September 2024

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)Antibodies

30 September 2024

Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe HypertriglyceridemiaAntibodies

30 September 2024

Valerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics CompanyMore News

29 September 2024

Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial HypertensionSmall Molecules

29 September 2024

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaSmall Molecules

29 September 2024

AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung CancerAntibodies

29 September 2024

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma PatientsDNA RNA and Cells

29 September 2024

CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second lineDNA RNA and Cells

29 September 2024

Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO CongressAntibodies

27 September 2024

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseasesAntibodies

27 September 2024

Septerna Announces Initiation of Phase 1 Clinical Trial with SEP-786, a Novel Oral Small Molecule PTH1R Agonist for the Treatment of HypoparathyroidismSmall Molecules

27 September 2024

BlueRock Therapeutics’ Investigational Cell Therapy Bemdaneprocel for Parkinson’s Disease Shows Positive Data at 24-MonthsDNA RNA and Cells

27 September 2024

TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myelomaAntibodies

27 September 2024

Dupixent approved in the US as the first-ever biologic medicine for patients with COPDAntibodies

27 September 2024

Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic SyndromeDNA RNA and Cells

27 September 2024

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in AdultsSmall Molecules

26 September 2024

Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back AtherosclerosisDNA RNA and Cells

26 September 2024

AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson’s DiseaseSmall Molecules

26 September 2024

Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024Antibodies

26 September 2024

Capstan Therapeutics to Present Preclinical Data on Lead In Vivo Chimeric Antigen Receptor (CAR)-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024DNA RNA and Cells

26 September 2024

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)Small Molecules

26 September 2024

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal CohortDNA RNA and Cells

26 September 2024

Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 ProgramSmall Molecules

26 September 2024

LEO Pharma Presents Late-Breaking Results from the Phase 2a Mechanism of Action Trial of Temtokibart and Dupilumab in Moderate-to-Severe Atopic Dermatitis at the 2024 EADV Annual MeetingAntibodies

26 September 2024

ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic FibrosisDNA RNA and Cells

26 September 2024

MesoPher cell therapy increases 2-year RFS rate in resected pancreatic cancer by 50%; publication of phase II results in Journal of Clinical Oncology and Orphan Designation granted by FDA & EMADNA RNA and Cells

26 September 2024

Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancerSmall Molecules

26 September 2024

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic DisordersProteins and Peptides

26 September 2024

The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDAProteins and Peptides

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Ranibizumab (Lucentis) Biosimilars Pipeline Review

PSMA-Targeted Therapy Pipeline Review

TSLP Pipeline Review

Report Package: Bispecific Antibodies

CD73 Inhibitor Pipeline Review